EMA’s New Draft Guideline On Good Pharmacogenomic Practice - Implications For Personalized Medicine

Published date20 June 2016
Law FirmFoley & Lardner LLP
AuthorAntoinette F. Konski
Subject MatterClinical Trials,Comment Period,DNA,Draft Guidance,EU,Genetic Markers,Personalized Medicine,Pharmaceutical Industry,Prescription Drugs

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT